Skip to main content
Clinical Trials/NCT05436379
NCT05436379
Completed
Not Applicable

Treatment, Emotion, and Neuromodulation of Depression (TREND) Study

Erika Forbes1 site in 1 country21 target enrollmentJune 17, 2022
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Erika Forbes
Enrollment
21
Locations
1
Primary Endpoint
depression severity
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The investigators will administer theta burst stimulation (TBS) in efforts to observe a decrease in severity of reported depression symptoms. A subset of participants will receive positive affect training during this intervention.

Detailed Description

The study has a longitudinal design in which participants complete a baseline assessment, 20 or 30 theta burst stimulation (TBS) sessions, a post-TBS assessment, and a follow-up assessment 4 months later. Ideally, TBS sessions will be delivered two or three times a day, 5 days/week, for 2 weeks. This procedural design of a shorter treatment duration is based on findings of pattern of improvement and newly developed SAINT protocol. A subset of participants will receive training in enhancing positive affect, with 10 training sessions occurring between pairs of TBS sessions. In this study, "response" to intervention will be defined as a greater than 50% decrease in severity of depression symptoms reported by participants.

Registry
clinicaltrials.gov
Start Date
June 17, 2022
End Date
November 30, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Erika Forbes
Responsible Party
Sponsor Investigator
Principal Investigator

Erika Forbes

Professor

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Current Diagnostic and Statistical Manual (DSM-5) Depressive Disorder

Exclusion Criteria

  • Bipolar disorder (lifetime)
  • Obsessive-compulsive disorder (lifetime)
  • History of psychosis
  • Daily use of nicotine
  • Past-month use of cocaine, amphetamines, Methyl enedioxy methamphetamine (MDMA), Phencyclidine (PCP), Ketamine, or gamma-hydroxybutyrate (GHB)
  • Past 6 month substance use disorder
  • Binge drinking (using NIAAA criteria) within the past week, alcohol use in the past 12 hours
  • Neurological disorders: Epilepsy, Parkinson's Disease, brain tumor, brain injury, stroke
  • History of head trauma with a loss of consciousness (e.g., concussion)
  • History of seizures

Outcomes

Primary Outcomes

depression severity

Time Frame: up to 1 year

Score on the Montgomery-Asberg Depression Rating Scale (MADRS), administered by a study team member

Study Sites (1)

Loading locations...

Similar Trials